• Journal of Chest Surgery
• /
• 제16권1호
• /
• pp.91-96
• /
• 1983

A study was carried out to observe the clinical progress and results after modified Blalock-Taussing shunts on II patients with cyanotic complex heart diseases unsuitable for corrective surgery. The operation was performed by interposing a vascular prosthesis [PTEE] between the left subclavian artery and the left pulmonary artery. Vascular prostheses larger than the diameter of left subclavian artery were selected. The results were as follows: 1. The postoperative courses in 10 patients were uneventful without any complications. One patient died of low cardiac output syndrome immediate postoperatively. 2. The average value of RBC count before operations was 751.2291.68 [xl00]/cubic mm. It was decreased to 588.11 90.45 [xl 0,000]/cubic mm. After the operation. 3. The average value of Hemoglobin before operations was 20.07 3.01 mg/dl. The value was decreased to 15.361.68mg/dl after the operation. 4. The value of Hematocrit before operations was 62.878.89%. The value was decreased to 49.6 5.84% 5. Patency after the shunt operations using PTFE was good for maximal 16 months follow-up period. 6. The physiological impairment like anoxic spells, degree of cyanosis and other clinical symptoms were markedly improved after the shunt operations. Although a longer follow-up seems to be necessary to assess the validity of these shunts, the early results were encouraging.

• 대한의용생체공학회:학술대회논문집
• /
• 대한의용생체공학회 1994년도 춘계학술대회
• /
• pp.105-108
• /
• 1994

A comparative study was made of the valvular sounds produced by normal prosthetic valves with thrombosed prosthetic valves. Comparisons of the closing sound were made for the power frequency spectra associated with individual valves. We used periodogram approach to obtain the spectral characteristics of the valve. Spectral analysis system was tested in mock circulatory system by comparing normal valves with those produced by the same valves but having simulated thrombosis at the hinge of the valve. The heart sounds was recorded from two patients having normal mechanical valve and thrombosed mechanical valve. The estimated spectrum of the thrombosed mechanical valve displayed lower apparent peak frequency than that of the normal valve. The results showed that frequency spectra gave information pertinent to the valve malfunction. Sound spectral analysis is simple and alternative diagnostic tool for early detection of prosthetic valve mal function.

• Journal of Chest Surgery
• /
• 제20권2호
• /
• pp.223-229
• /
• 1987

Doppler echocardiography provides valuable information regarding prosthetic heart valve function rather than structure. There are three methods of expressing the severity of mitral valve obstruction: the transvalvular pressure gradient, effective valve area, and pressure half-time. Of these, the transvalvular pressure gradient [~p] can be determined by the measurement of maximum transvalvular blood flow velocity [V] according to the modified Bernoulli`s equation [gp=4V*]. Eleven patients, who underwent mitral valve replacement with Duromedics mechanical prostheses, and 17 normal persons were investigated. There were significantly higher calculated pressure gradients in prosthetic than normal mitral valves [9.*10*2.22mmHg-vs-3.26*0.99mmHg:p<0,01], and there was a inverse relationship between pressure gradient and prosthetic valve size [11.17*0.%mmHg in size 27mm and 29mm -v- 7.38*1.12mmHg in size 31mm and 33mm; r=0.85, p<0.01] The noninvasive Doppler technique should be useful in the diagnosis of prosthetic valve obstruction.

• Journal of Chest Surgery
• /
• 제28권6호
• /
• pp.557-564
• /
• 1995

Microvel knitted double velour vascular grafts coated with biodegradable algin were evaluated in the canine experimental model as a new biologically coated Dacron graft. Three series of implantations were conducted involving the insertion of 6 mm diameter grafts in the abdominal aortae of mongrel dogs. The first series used the regular Microvel vascular grafts coated with algin,whereas the second and third series used Hemashield [collagen-coated grafts and the regular Microvel grafts with preclotting,respectively as control groups. Each series involved the implantation of one prosthesis for each of 2 preselected periods,namely 3 months and 6 months. In addition,algin-impregnated grafts were implanted for 4 hours,72 hours,2 weeks,and 4 weeks. All grafts were patent when the animals were sacrificed at intervals ranging from 4 hours to 6 months. Histological examinations revealed no obvious or significant differences in the healing characteristics of the algin-coated grafts and the control grafts after 3 months and 6 months of implantation. Endothelial cell-like cells were present on the midsegments of all grafts explanted from animals sacrificed after 3 months and 6 months,except a suspicious finding in the 3 month-implantation animal of a preclotted graft. With special stains,the algin became invisible between the polyester filaments during the first 3 months of implantation. This study has demonstrated that the use of a biodegradable algin coating is a feasible approach as biological sealants for textile arterial prostheses.

• Journal of Chest Surgery
• /
• 제33권1호
• /
• pp.45-50
• /
• 2000

Background: The CarboMedics prosthetic heart valve was produced in an attempt to improve the existing valve designs and was especially concerned with easily the implantation and further reduction of turbulence. Precise positioning of the valve in situ was achieved by the abilityof the valve to rotate relative to the sewing ring. Improved monitoring is possible due to increased radiopacity and the dacron sewing ring is coated with carbon to reduce pannus overgrowth. The leaflets have an opening angle of 78 degrees that apparently allows a rapid synchronous closure The aim of this study was to analyze the clinical performance of the CarboMedics valve prostheses(45 mitral 13 aortic and 7 double aortic-mitral valve replacement) were implanted in 65 patients(mean age 48.75$\pm$9.74 years) Result: The operative mortality was 3.1%(2/65) causes of death were low cardiac output syndrome. Total follow up was 1831 patient-months and mean follow up was 29.06$\pm$10.97 months/patient. No structural failure hemorrhage valve thrombosis and late death have been observed. Embolism occurred at a rate of 0.65%/Patient-year. Actuarial survival and thrombo-mbolism free rate at 36 months were 96.9% and 98.4% respectively. Consclusions: The CarboMedics valve stands for low valve related complicatons.

• Journal of Chest Surgery
• /
• 제25권6호
• /
• pp.661-671
• /
• 1992

From March 1988 to May 1991, 140 CarboMedics cardiac valve prostheses[75 mitral, 9 aortic and 28 double aortic-mitral] were implanted in 112 consecutive patients[mean age 36.7$\pm$11.6 years, male/female 48/76] by one surgical team operating on adult cardiac patients at Kyoungpook University Hospital Associated Surgical procedures were performed in 19 patients[16.9%]. Total follow up represented 2,345 patient-months[mean 22.4 months] and was 100% complete. Eighty-two patients[73%] were in NYHA functional class IIIor IV preoperatively and 102 patients [95%] were in class I or II postoperatively. Hospital[30 day] mortality was 4.4%, [3/75 mitral, 1/9 aortic, 1/28 double valve replacement] and late death was 1.7%. [1 /74 mitral, 1 /28 double valve replacement] The actuarial survival at 36 months was 94.0% after mitral, 80% after aortic, 92% after double valve replacement, and 93.2% for the total group. The linearized incidence of valve relater death, prosthetic valve thrombosis, anticoagulant related hemorrhage, and reoperation was 1.00%/pt-yr, 0.51%/pt/yr, 0.51%/pt-yr, and 0.51%/pt-yr respectively. The 36 month rates of freedom from valve replated death, thromboembolism, endocarditis, anti-coagulant related hemorrages, and reoperation were 98.75%, 99.08%, 100%, 99.04%, and 99.08% respectively. The 36 month rate of freedom from all valve related complications and deaths including hospital mortality was 90.2%. These fact suggest that the CarboMedics heart valve has excellent short-term result, low incidence of valve-related complications and valve dysfunction, and additional long term follow up study is necessary.

• Journal of Chest Surgery
• /
• 제25권2호
• /
• pp.137-148
• /
• 1992

Until March 1991, 435 St. Jude Medical valves and 330 CarboMedics valves were implanted in 358 and 251 patients, respectively. 300 patients were male and 309 were female with the mean age of 35.6 years[from 2 month to 68 years]. 458 valves were implanted in the mitral, 272 in the aortic, 25 in the tricuspid, and 10 in the pulmonic position. Postoperatively, all patients except for very young patients were given coumadin with or without dipyridamole for anticogulation Operative mortality was 7.3%[45 deaths per 618 operations]. A total follow-up of 1244.8 patient-years was achieved for the operative survivors with a follow-up rate of 96.8%, [mean follow-up period=26.3 months /patient, ranging from 1 to 80 months]. Functional improvement was evident; 66.7% of these patients were in NYHA functional class III or IV preopratively, whereas 98.4% are in class I or II pos-toperatively. There occurred 13 late deaths[7 valve-related] and 55 valve-related complications. Linearized rates of late death and valve-related complications were 1.0%/ patient-year, 4.42%/patient-year, respectively. Rates of thromboembolism, anticoagluation-related hemorrhage were 1.12%/patient-year, 1.69% /patient-year, respectively. Actuarial survival at 5 years is 96.0% and complication-free survival at 5 years is 83.9%. No difference in survival and incidence of complications was found between the St. Jude and CarboMedics valves. On the basis of this experience, we believe that the pyrolytic carbon bileaflet mechanical valves are safe and preferable choice among current valve prostheses.

• Journal of Chest Surgery
• /
• 제16권4호
• /
• pp.458-469
• /
• 1983

Between October, 1978, and December, 1982, Glutaraldehyde-stablized pericardial xenografts [Ionescu-Shiley valve] were used for heart valve replacement in 409 patients.[251 mitral, 49 aortic, 11 tricuspid, and 98 multiple valve replacement]. There were 31 early deaths [7.6%], and 371 operative survival were observed for a total of 507.6 years over a period of 1 to 44 months. [mean 17 months]. Actuarial analysis of late results indicates an excepted survival rate at 4 years of 86.25.4% for patients with mitral, 79.37.1% for patients with aortic valve replacement. Actuarial survival rates for total patients at 4 years was 77.88.2%. The rate of systemic embolism has been 1.6% per patient-year for mitral and 1.8% per patient-year for aortic group in the presence of anticoagulation treatment. Among the 6 embolic episodes, 2 patients were died. The incidence of hemorrhagic complication was 1.3% per patient-year for anticoagulated patients. There were 6 confirmed valve failures, five in mitral and one in aortic position. Re-replacement of destructed valve was performed in one patient and others were treated medically. Among the 6 episodes, 3 occurred in children [Below 15 years], it account almost 9 times higher than adult. Our clinical data compare very favorable with those obtained with other available prostheses and tissue valves, but it should be considered to give short-term anticoagulation therapy to hemodynamically stable patients and aortic valve patients, and other prosthetic valve must be considered to use in children.

• Journal of Chest Surgery
• /
• 제33권8호
• /
• pp.643-647
• /
• 2000

From March 1988 to June 1994, 275 CarboMedics cardiac valve prostheses(199 mitral, 70 aortic and 3 tricuspid) were implanted in 226 consecutive patients(mean age 39 years, male/female 90/136) by one surgical team operating on adult cardiac patients at Kyungpook University Hospital. Total follow up represented 16,848 patient-months(mean 76 months) and follow up rate was 96%. One hundred and forty-nine patients(66%) wer in NYHA functional class III or IV preoperatively, and 204 patients(99.5%) were in class I or II postoperatively. Early mortality was 4.9% and late death was 9.3%. The actuarial survival at 81 months was 86.l2$\pm$3.1%. The linearized incidence of valve-related death, prosthetic valve thrombosis, anticoagulation-related hemorrhage, non-structural dysfunction and reoperation were 0.71%, 0.43%, 0.07%, 0.21%, and 0.14% respectively. The 81-month rate of freedom from all valve related complications and deaths including hospital mortality was 88.1$\pm$2.5%. Thee facts suggest that the CarboMedics cardiac valve has excellent result, low incidence of valve-related complications and no structureal deterioration.

• Journal of Chest Surgery
• /
• 제36권7호
• /
• pp.463-471
• /
• 2003

대동맥판막 치환술과 동반시행한 승모판막 성형술의 장기 결과에 대해서는 잘 알려져 있지 않다. 본 연구는 대동맥판막 및 승모판막 질환에서의 대동맥판막 치환술과 동반시행한 승모판막 성형술의 조기 및 장기 수술 결과에 대해 알아보고자 하였다. 대상 및 방법: 1990년 9월부터 2002년 4월까지 세종병원에서 대동맥판막 치환술과 승모판막 성형술을 받은 45명의 환자를 대상으로 후향적으로 조사하였다. 남녀비는 28 : 17명이었고 평균 연령은 47$\pm$17세였다. 심방세동은 12명에서 있었고 3명은 과거에 심장수술을 받았다. 승모판막 질환은 폐쇄부전 34명, 협착 3명, 폐쇄부전 및 협착 혼합형이 8명이었다. 승모판막 질환의 원인으로는 류머치스성 24명, 퇴행성 11명, 기능성 8명, 허혈성과 심내막염이 각각 1명이었으며 수술 소견상 판륜확장 31명, 건삭확장 19명, 판첨비후 19명, 교련응합 13명, 건삭융합 10명, 건삭판열 6명 등이었다. 수술은 모든 환자에서 대동맥판막(기계판막 32명, 조직판막 12명, 폐동맥자가판막 1명)을 치환하였고 승모판막 성형술은 판륜성형술이 32명에서, 판첨성형술은 29명에서 54건이 시행되었다. 총체외순환시간 및 대동맥차단시간은 각각 204$\pm$62분, 153$\pm$57분이었다. 결과: 조기사망은 1명(2.2%)으로 술 후 저심박증후군으로 사망하였다. 57$\pm$37개월을 추적조사한 결과 1명(2.3%)이 암으로 사망하였으며 10년 actuarial survival 96$\pm$4%였다. 승모판 폐쇄부전은 11명에서 II혹은 III를 보였고, 중등도의 승모판 협착은 3명에서 있었으며 판막 관련 재수술은 2명에서 승모판막 질환으로 1명에서 대동맥판막 질환으로 필요하였다. 승모판막 폐쇄부전과 협착으로부터의 자유도는 각각 64$\pm$11%와 86$\pm$8%였으며 재수술로부터의 자유도는 89$\pm$7%였다. 결론: 대동맥판막 치환술과 동반시행한 승모판막 성형술은 양호한 조기 및 장기 생존율을 보이며 향후 승모판막 폐쇄부전 및 협착 재발률을 더 낮추기 위해서는 특히 류머치스성 승모판막 질환 경우에는 성형술에 대한 적절한 술기 및 적응증의 선택이 중요하리라 생각된다.